Novartis Gains Phase II COPD Agent In Deal Worth Up To $375 Mil.
This article was originally published in The Pink Sheet Daily
Executive SummaryNovartis will assume Phase III testing of anti-muscarinic from U.K. companies Vectura and Arakis. AD 237 will be evaluated in head-to-head comparison against Pfizer/Boehringer Ingelheim's Spiriva; companies believe AD 237 has a better safety profile than tiotropium.
You may also be interested in...
'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.